Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
The progression of atherosclerosis remains a major cause of morbidity and mortality. Plaque formation is an immunological response driven by a number of risk factors, and reduction of risk is the primary goal of treatment. The role of LDL-C is well established and statins have proved effective drugs...
Main Author: | Helen Vosper |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-01-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | https://doi.org/10.4137/CMC.S7601 |
Similar Items
-
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
by: Ayman A Hussein, et al.
Published: (2010-04-01) -
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
by: Klaus G Parhofer
Published: (2009-11-01) -
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed  dyslipidemias and primary hypercholesterolemia
by: Adie Viljoen, et al.
Published: (2010-05-01) -
Effects of extended-release niacin with laropiprant in high-risk patients.
by: Landray, M, et al.
Published: (2014) -
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
by: Farnier M, et al.
Published: (2014-05-01)